[Compulsory measures and pathological creatine kinase levels in psychiatric in-patients].
The aim of this study was to investigate the association of compulsory measures (CM) with pathological Creatine Kinase (CK) levels in 317 patients admitted to a secure psychiatric ward. The assumptions is that CK-activity is increased prior to administration of CM because increases in CK-levels may represent aggressive behaviour as precursors of a higher chance of administrating CM. The CK-levels were assessed immediately following admission. During the course of the patients' stay the frequency of different CM was assessed by the use of the Staff Observation Aggression Scale. In a CHAID analysis pathological CK-levels were associated with subsequent administration of CM. Lifetime aggression and main diagnosis were associated with administration of CM as well. In a ROC analysis concerning pathological CK-activity the AUC for subsequent administration of CM was 70.5 % with a sensitivity of 73.5 % and a specifity of 67.5 %. Despite some methodological shortcomings the study indicates that it could be useful to measure CK-activity at the time of admission because pathological levels may indicate an increased probability of administration of CM subsequent to aggressive behaviour.
Klinik für Psychiatrie und Psychotherapie - Psychosomatik, Klinikum Frankfurt a. M.-Höchst, Akademisches Lehrkrankenhaus der Universität Frankfurt.
Michael
M
Grube
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000374:Aggression / Q000502:physiology* / Q000523:psychology*; D001143:Arousal / Q000502:physiology*; D003068:Coercion; D003134:Commitment of Persons with Psychiatric Disorders; D003402:Creatine Kinase / Q000097:blood*; D005260:Female; D005858:Germany; D006801:Humans; D007902:Length of Stay; D008297:Male; D001523:Mental Disorders / Q000201:enzymology* / Q000523:psychology / Q000628:therapy*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011594:Psychometrics; D011619:Psychotropic Drugs / Q000008:administration & dosage*; D012149:Restraint, Physical; D012307:Risk Factors; D012637:Security Measures; D012931:Social Environment; D055815:Young Adult
D011619:Psychotropic Drugs; D003402:Creatine Kinase